SNP rs13194504 AA Genotype Linked to Severity of Tardive Dyskinesia
By Elana Gotkine HealthDay Reporter
TUESDAY, June 25, 2024 -- For patients with schizophrenia, the single-nucleotide polymorphism (SNP) rs13194504 AA genotype is associated with reduced severity of tardive dyskinesia (TD), but is not associated with occurrence, according to a study recently published in Human Psychopharmacology: Clinical & Experimental.
Ruoyu Wang, from the Centre for Addiction and Mental Health in Toronto, and colleagues tested SNPs rs13194504 and rs210133 for the association with the occurrence and severity of TD among 172 patients with schizophrenia who were recruited for four studies at three clinical sites in Canada and the United States.
The researchers found that there was an association for the rs13194504 AA genotype with reduced severity for TD, as measured by the Abnormal Involuntary Movement Scale (AIMS), but not for occurrence of TD. No significant association was seen for rs210133 with either TD occurrence or AIMS scores.
"Our results suggest that the SNP rs13194504 AA genotype may be associated with decreased severity of TD, thus pointing to a potential protective effect against TD," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Better Adherence to Antipsychotics Linked to Lower Vehicle Crash Risk
MONDAY, June 9, 2025 -- For drivers with schizophrenia, better adherence to antipsychotic medications is associated with lower motor vehicle crash risk, according to a study...
American Psychiatric Association, May 17-21
The annual meeting of the American Psychiatric Association was held from May 17 to 21 in Los Angeles. Participants included clinicians, academicians, allied health...
Exposure to Maternal Cannabis Use Disorder Ups Risk for Youth Behavioral Disorders
MONDAY, March 24, 2025 -- Children exposed to maternal cannabis use disorder (CUD) during pregnancy and postpartum have an increased risk for later behavioral disorders, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.